Peregrine Capital Management’s Corcept Therapeutics CORT Stock Holding History

Peregrine Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-387,602	Closed	-$4.69M	–	311
2019 Q4	$4.69M	Sell	387,602 -892	-0.2%	-$12.4K	0.12%	236
2019 Q3	$5.49M	Sell	388,494 -89,549	-19%	-$1.1M	0.15%	216
2019 Q2	$5.33M	Sell	478,043 -2,466	-0.5%	-$27.5K	0.13%	235
2019 Q1	$5.64M	Sell	480,509 -1,852	-0.4%	-$23K	0.14%	241
2018 Q4	$6.44M	Buy	482,361 +160,562	+50%	+$2.12M	0.18%	221
2018 Q3	$4.51M	Buy	+321,799	New	+$4.5M	0.11%	239

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Peregrine Capital Management's CORT Position: Q1 2020 in Review

Peregrine Capital Management sold out of Corcept Therapeutics (CORT) in Q1 2020, closing a stake of 387,602 shares — an estimated $4.69M sold.

Peregrine Capital Management first reported a position in CORT in Q3 2018 and held it in 6 quarters. The position peaked at $6.44M in Q4 2018. 204 funds tracked by Wall St. Rank hold CORT as of Q1 2020.

Peregrine Capital Management reported no remaining Corcept Therapeutics position as of Q1 2020 after selling out during the quarter.
Peregrine Capital Management sold 387,602 Corcept Therapeutics shares in Q1 2020, an estimated $4.69M.
Peregrine Capital Management first reported a position in Corcept Therapeutics in Q3 2018 and held it in 6 quarters.
Peregrine Capital Management's Corcept Therapeutics position peaked at $6.44M in Q4 2018.
204 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2020.

Based on Peregrine Capital Management's 13F filing for Q1 2020, filed 17 Apr 2020.